Australia markets closed

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
147.52-1.27 (-0.85%)
At close: 04:00PM EDT
147.51 -0.01 (-0.01%)
After hours: 07:59PM EDT

Johnson & Johnson

One Johnson & Johnson Plaza
New Brunswick, NJ 08933
United States
732 524 0400
https://www.jnj.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees131,900

Key executives

NameTitlePayExercisedYear born
Mr. Joaquin DuatoCEO & Chairman6.21M14.99M1963
Mr. Joseph J. Wolk CPAExecutive VP & CFO3.17MN/A1967
Dr. Peter M. Fasolo Ph.D.Executive VP & Chief Human Resources Officer2.15MN/A1963
Ms. Jennifer L. TaubertExecutive VP & Worldwide Chairman of Innovative Medicine3.1MN/A1964
Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine, R&D8.57MN/A1958
Mr. Robert J. Decker Jr.Controller & Chief Accounting OfficerN/AN/A1972
Mr. James SwansonExecutive VP & Chief Information OfficerN/AN/A1966
Ms. Jessica MooreVice President of Investor RelationsN/AN/AN/A
Mr. Dirk BrinckmanChief Compliance OfficerN/AN/AN/A
Ms. Elizabeth ForminardExecutive VP & General CounselN/AN/A1971
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Corporate governance

Johnson & Johnson’s ISS governance QualityScore as of 1 April 2024 is 2. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 2; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.